Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.47 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | REN | P00797 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | FCER2 | P06734 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14756043 | 0.81 | NPC1 (0.69) | NPC1RAB9AACEPSMB5KMT2A | |
| SCHEMBL15116458 | 0.81 | NPC1 (0.69) | NPC1RAB9AACEPSMB5KMT2A | |
| SCHEMBL18310372 | 0.79 | KMT2A (0.56) | PSMB5KMT2AALDH1A1LMNAANPEP | |
| SCHEMBL7283440 | 0.78 | BACE1 (0.59) | ACEREN | |
| Dl-Phenylalanine SCHEMBL1253618 | 0.77 | SLC7A5 (0.59) | LTA4HANPEPRNPEPDNPEP | |
| Phenylalanine SCHEMBL1253619 | 0.77 | SLC7A5 (0.59) | LTA4HANPEPRNPEPDNPEP | |
| Hydrochloric Acid SCHEMBL11139146 | 0.77 | CTSD (0.60) | ALDH1A1REN | |
| Hydrochloric Acid SCHEMBL11023528 | 0.77 | CTSD (0.60) | ALDH1A1REN | |
| SCHEMBL20054669 | 0.76 | NPC1 (0.65) | NPC1RAB9AKMT2AALDH1A1LMNA | |
| SCHEMBL23812563 | 0.76 | LAP3 (0.64) | NPC1RAB9ALTA4HANPEPRNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2433655-A2 | Homoarginine-prodrugs of amphetamine | Kempharm, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2433654-A2 | Citrulline and homocitrulline prodrugs of amphetamines and processes for making and using the same | Kempharm, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-8101661-B2 | Polar hydrophilic prodrugs and non-standard amino acid conjugates of amphetamine and other stimulants and processes for making and using the same | KEMPHARM, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101661-B2 | Polar hydrophilic prodrugs and non-standard amino acid conjugates of amphetamine and other stimulants and processes for making and using the same | KEMPHARM, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110213034-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SHIRE LLC | 2011-09-01 | — | — | US | disclosed |
| US-20100292337-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SHIRE LLC | 2010-11-18 | — | — | US | disclosed |
| US-20100292337-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SHIRE LLC | 2010-11-18 | — | — | US | disclosed |
| US-20100292336-A1 | Polar Hydrophilic Prodrugs and Non-Standard Amino Acid Conjugates of Amphetamine and Other Stimulants and Processes for Making and Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
| US-20100292336-A1 | Polar Hydrophilic Prodrugs and Non-Standard Amino Acid Conjugates of Amphetamine and Other Stimulants and Processes for Making and Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
| US-7772222-B2 | Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-10 | — | — | US | disclosed |
| US-7772222-B2 | Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090239949-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SHIRE LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090239949-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SHIRE LLC | 2009-09-24 | — | — | US | disclosed |
| US-20080207757-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080207757-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-28 | — | — | US | disclosed |
| WO-2008098151-A2 | POLAR HYDROPHILIC PRODRUGS OF AMPHETAMINE AND OTHER STIMULANTS AND PROCESSES FOR MAKING AND USING THE SAME | KEMPHARM, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292337-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SLC6A2, SLC6A3, SLC18A2 | NPC1 1495/4885RAB9A 2253/4885ACE 770/4885 |
| US-20090239949-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SLC6A2, SLC6A3, SLC18A2 | NPC1 1495/4885RAB9A 2253/4885ACE 770/4885 |
| US-20100292336-A1 | Polar Hydrophilic Prodrugs and Non-Standard Amino Acid Conjugates of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SLC18A2, SLC6A19, SLC6A2 | NPC1 2023/4885RAB9A 1703/4885ACE 795/4885 |
| US-20110213034-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SLC6A3, SLC6A2, SLC6A15 | NPC1 1336/4885RAB9A 1791/4885ACE 650/4885 |
| US-20080207757-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SLC6A2, SLC6A3, SLC18A2 | NPC1 1495/4885RAB9A 2253/4885ACE 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.